Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome

What Was Tested

The paper reports a study of Angiotensin II in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

Angiotensin II, acting via the angiotensin II type 1 (AT(1)) receptor, is central to the development of endothelial dysfunction.

The effect of AT(1) receptor blockade on NOS expression and activity in humans with early insulin resistance syndrome (INSR) has not been previously investigated.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Subjects were randomized to receive telmisartan or placebo (1 month of each) in a two-period crossover study with a 1-week washout period in between.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

SI (Stiffness index, a measure of large artery stiffness) and RI (Reflection index, small- to medium-sized arterial stiffness) were measured using digital photoplethysmography.

Haemodynamic parameters [Heart rate (HR), Systolic blood pressure (SBP), Diastolic BP (DBP) and systemic vascular resistance index (SVRI)] were measured non-invasively using trans-thoracic bioimpedance.

What Was Measured

PubMed files the paper under topics including Angiotensin II, Arteries, Benzimidazoles, Benzoates, Blood Pressure, Cardiovascular System and Diabetes Mellitus, Type 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with insulin resistance, prediabetes & type 2 diabetes.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Blood pressure), a journal based in England.

More context: the Angiotensin II compound page, Insulin resistance, prediabetes & type 2 diabetes research.